Loading
In a Canadian programme sequencing the genomes of advanced pancreatic cancers in real time, tumours without a KRAS mutation repeatedly carried NRG1 fusions, and patients treated with HER-family blockers on the strength of that finding responded. It showed that fusion testing in KRAS wild-type disease changes treatment.
Analysis of whole-genome and transcriptome sequencing from patients with advanced pancreatic ductal adenocarcinoma in the COMPASS trial and related cohorts at BC Cancer and the Ontario Institute for Cancer Research. NRG1 fusions with several different partner genes were identified in a subset of the KRAS wild-type tumours and in none of the KRAS-mutant cases, and were confirmed at the RNA level.
Patients with NRG1 fusion-positive tumours treated with ERBB-targeting drugs such as afatinib had radiological responses and falls in tumour markers. The authors argue for RNA-based fusion testing in every KRAS wild-type pancreatic cancer.
Together with the German MASTER report, this paper is why guidelines recommend comprehensive profiling with fusion detection in KRAS wild-type pancreatic cancer.
Shares Zenocutuzumab, NRG1, Afatinib, Wild-type (WT).
Shares Zenocutuzumab, NRG1, Wild-type (WT), HER3.
Shares BC Cancer, Clinical Cancer Research, RNA sequencing & expression profiling, KRAS.
Shares Zenocutuzumab, NRG1, HER3, KRAS wild-type pancreatic ductal adenocarcinoma.
Shares NRG1, Wild-type (WT), Clinical Cancer Research, KRAS wild-type pancreatic ductal adenocarcinoma.
Shares NRG1, Clinical Cancer Research, Receptor tyrosine kinase activation, RNA sequencing & expression profiling.
Shares Zenocutuzumab, NRG1, HER3, Receptor tyrosine kinase activation.
Shares Zenocutuzumab, NRG1, KRAS.